0.20Open1.77Pre Close17 Volume7 Open Interest45.50Strike Price1.11KTurnover77.04%IV5.36%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.3025Delta0.0935Gamma62.97Leverage Ratio-0.1774Theta-0.0015Rho-19.05Eff Leverage0.0169Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet